Anti-aggregatory drugs: I. Platelet receptor antagonists

Bibliography

• WORLD HEALTH ORGANISATION (WHO): World healthreport 1998: life in the 21st century: a vision for all. WHO Geneva, Switzerland (1998).
   Google Scholar
• FUSTER V, BADIMON L, BADIMON JJ, CHESEBRO JH: Thepathogenesis of coronary artery disease and the acute coronary syndromes. New Engl. J. Med. (1992) 326:242–250.
   PubMed Web of Science ®Google Scholar
• •Background of vascular disease.
   Google Scholar
• FALK E, SHAH PK, FUSTER V: Coronary plaque disrup- tion. Circulation (1995) 92:657–671.
   PubMed Web of Science ®Google Scholar
• LIBBY P: Molecular basis of the acute coronary syndrome. Circulation (1995) 91:2844–2850. Biological background of coronary disease.
   PubMed Web of Science ®Google Scholar
• ANTIPLATELET TRIALIST'S COLLABORATION: Collabora-tive overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. (1994) 308:81–106.
   Google Scholar
• ANTIPLATELET TRIALIST'S COLLABORATION: Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br. Med. J. (1988) 296:320–331.
   PubMedGoogle Scholar
• RISC STUDY GROUP: Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary disease. Lancet (1990) 336:827–830.
   PubMedGoogle Scholar
• LEWIS HD, DAVIS JW, ARCHIBALD DG et al.: Protectiveeffects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. New Engl. J. Med. (1983) 309:396–403.
   Google Scholar
• ISIS-2 COLLABORATIVE GROUP: Randomised trial ofintravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet (1988) 332:349–360.
   Google Scholar
• VERSTRAETE M, ZOLDHELYI P: Novel antithrombotic drugs in development. Drugs (1995) 49:856-884. Overview of new antithrombotic drugs.
   Google Scholar
• JENNINGS LK, PHILLIPS DR: Purification of glycoprotein ID) and Ma from human platelet plasma membranes and characterization of a calcium-dependent glycoprotein IIb/IIIa complex. J. Biol. Chem. (1982) 257:10458–10466
   PubMed Web of Science ®Google Scholar
• DU X, PLOW EF, FRELINGER AL, O'TOOLE TE, LOFTUS JC, GINSBERG MH: Ligands 'activate' integrin anb133 (platelet GP Ilb/Ifia). Cell (1991) 65:409–416.
   PubMed Web of Science ®Google Scholar
• D'SOUZA SE, GINSBERG MH, BURKE TA, PLOW EF: Localization of an arg-gly-asp recognition site within an integrin adhesion receptor. Science (1988) 242:91–93.
   PubMed Web of Science ®Google Scholar
• RUOSHLATI E, PIERSCHBACHER MD: Arg-Gly-Asp: a versatile cell recognition signal. Cell (1986) 44:517–518.
   PubMedGoogle Scholar
• KNIGHT CG, MORTON LF, ONLEY DJ et al.: Collagen-platelet interaction: Gly-Pro-Hyp is uniquely specific for platelet GP VI and mediates platelet activation by collagen. Cardiovasc. Res. (1999) 41:450–457.
   PubMed Web of Science ®Google Scholar
• KEHREL B, WIERWILLE S, CLEMETSON KJ et al.: Glycopro-tein VI is a major collagen receptor for platelet activa-tion: it recognizes the platelet-activating quaternary structure of collagen, whereas CD 36, glycoprotein Ilb/Ifia, and von Willebrand factor do not. Blood (1998) 91:491–499.
   PubMed Web of Science ®Google Scholar
• INOUE K, OZAKI Y, SATOH K et al.: Signal transduction pathways mediated by glycoprotein Ia/fia in human platelets: comparison with those of glycoprotein VI. Biochem. Biophys. Res. Commun. (1999) 256:114–120.
   PubMed Web of Science ®Google Scholar
• NAKAMURA T, KAMBAYASHI J, OKUMA M, TANDON NN: Activation of the GP Ilb-IIIa complex induced by platelet adhesion to collagen is mediated by both cc201 integrin and GP VI. J. Biol. Chem. (1999) 274:11897–11903.
   PubMedGoogle Scholar
• FREDHOLM BB, ABRACCHIO MP, BURNSTOCK G et al.: Towards a revised nomenclature for P1 and P2 receptors. Trends Pharmacol Sci. (1997) 18:79–82.
   PubMed Web of Science ®Google Scholar
• NORTH RA, BARNARD EA: Nucleotide receptors. Curr. Opin. Neurobiol. (1997) 7:346–357.
   PubMed Web of Science ®Google Scholar
• ••Concise review of nucleotide receptors.
   Google Scholar
• BOARDER MR, HOURANI SMO: The regulation of vascular function by P2 receptors: multiple sites and multiple receptors. Trends Pharmacol. Sci. (1998) 19:99–107.
   PubMedGoogle Scholar
• ••Review of the role of purinoceptors in the vascular system.
   Google Scholar
• KUNAPULI SP: Multiple P2 receptor subtypes on platelets: a new interpretation of their function. Trends Pharmacol. Sci. (1998) 19:391–394.
   PubMedGoogle Scholar
• ••Review of platelet purinoceptors.
   Google Scholar
• BORN GVR: Adenosine diphosphate as a mediator of platelet aggregation in vivo: an editorial point of view. Circulation (1985) 72:741–742.
   PubMedGoogle Scholar
• JIN J, DANIEL JL, KUNAPULI SP: Molecular basis for ADP-induced platelet activation (II). J. Biol. Chem. (1998) 273:2030–2034.
   PubMed Web of Science ®Google Scholar
• DANIEL JL, DANGELMAIER C, JIN J, ASHBY B, SMITH JB, KUNAPULI SP: Molecular basis for ADP-induced platelet activation (0. J. Biol. Chem. (1998) 273:2024–2029.
   PubMed Web of Science ®Google Scholar
• GEIGER J, HONIG-LIEDL P, SCHANZENBACHER P, WALTER U: Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptors. Eur. J. Pharmacol. (1998) 351:235–246.
   PubMedGoogle Scholar
• GEIGER J, BRICH J, HONIG-LIEDL P ET AL.: Specific impairment of human platelet P2YAC ADP receptor- mediated signaling by the antiplatelet drug clopido-grel. Atheroscler. Thromb. Vasc. Biol. (1999) (In Press).
   Google Scholar
• JIN J, KUNAPULI SP: Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc. Natl. Acad. ScL USA (1998) 95:8070–8074.
   PubMed Web of Science ®Google Scholar
• TOLLEFSEN DM, FEAGLER JR, MAJERUS PW: The binding of thrombin to the surface of human platelets. J. Biol. Chem. (1974) 249:2646–2651.
   PubMedGoogle Scholar
• WORKMAN EF, WHITE GC, LUNDBLAD RL: Structure-function relationships in the interaction of fs20 F128a-thrombin with blood platelets. J. Biol. Chem. (1977) 252:7118–7123.
   PubMedGoogle Scholar
• VU TKH, HUNG DT, WHEATON VI, COUGHLIN SR: Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor acivation. Cell (1991) 64:1057–1068.
   PubMed Web of Science ®Google Scholar
• •Mechanism of thrombin receptor activation.
   Google Scholar
• VASSALLO RR, KIEBER-EMMONS T, CICHOWSKI K, BRASS LF: Structure/function relationships in the activation of platelet thrombin receptors by receptor-derived peptides. J. Biol. Chem. (1992) 267:6081–6085.
   PubMed Web of Science ®Google Scholar
• BRASS LF: Homologous desensitization of HEL cell thrombin receptors: distinguishable roles for proteolysis and phosphorylation. J. Biol Chem. (1992) 267:6044–6050.
   PubMedGoogle Scholar
• BRASS LF, VASSALLO RR, BELMONTE E, AHUJA M, CICHOWSKI K, HOXIE JA: Structure and function of the human platelet thrombin receptor: studies using monoclonal antibodies against a defined epitope within the receptor N-terminus. J. Biol. Chem. (1992) 267:13795–13798.
   PubMed Web of Science ®Google Scholar
• OFOSU FA, FREEDMAN J, DEWAR L, SONG Y, FENTON JW:A trypsin-like platelet protease propagates protease-activated receptor-1 cleavage and platelet activation. Biochem. J. (1998) 336:283–285.
   PubMedGoogle Scholar
• HUNG DT, WONG YH, VU TKH, COUGHLIN SR: The cloned platelet thrombin receptor couples to at least two distinct effectors to stimulate phosphoinositide hydrolysis and inhibit adenylyl cyclase. J. Biol. Chem. (1992) 267:20831–20834.
   PubMed Web of Science ®Google Scholar
• WHITTLE BJR, HAMID S, LIDBURY P, ROSAM AC: Specificity between the anti-aggregatory actions of prostacyclin, prostaglandin Ei and D2 on platelets. Adv. Exp. Med. Biol (1985) 192:109–125.
   PubMed Web of Science ®Google Scholar
• COLEMAN RA, HUMPHREY PPA, KENNEDY I, LUMLEY P: Prostanoid receptors: the development of a working classification. Trends Pharmacol Sci. (1984) 5:303–306.
   Google Scholar
• MAYEUX PR, MORTON HE, GILLARD J eta].: The affinities of prostaglandin H2 and thromboxane A2 for their receptor are similar in washed human platelets. Biochem. Biophys. Res. Commun. (1988) 157:733–739.
   Google Scholar
• HALUSHKA PV, MAIS DE, MAYEUX PR, MORINELLI T: Prostaglandin, thromboxane and leukotriene receptors. Ann. Rev. Pharmacol. Toxicol. (1989) 29:213–239.
   PubMedGoogle Scholar
• ••Overview of eicosanoid and leukotriene receptors.
   Google Scholar
• USHIKUBI F, NAKAJIMA M, HIRATA M, OKUMA M, FUJIWARA M, NARUMIYA S: Purification of the thromboxane A2/prostaglandin 112 receptor from human blood platelets. J. Biol. Chem. (1989) 264:16496–16501.
   PubMedGoogle Scholar
• HIRATA M, HAYASHI Y, USHIKUBI F et al.: Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature (1991) 349:617–620.
   PubMed Web of Science ®Google Scholar
• RAYCHOWDHURY MK, YUKAWA M, COLLINS LJ, MCGRAIL SH, KENT C, WARE JA: Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. J. Biol. Chem. (1994) 269:19256–19261.
   PubMed Web of Science ®Google Scholar
• HIRATA T, USHIKUBI F, KAKIZUKA A, OKUMA M, NARUMIYA S: Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. J. Clin. Invest. (1996) 97:949–956.
   Google Scholar
• COLEMAN RA: Comparison of the actions of U-46619, a prostaglandin 112-analogue, with those of prosta-glandin 112 and thromboxane A2. Br. J. Pharmacol. (1981) 73:773–778.
   PubMed Web of Science ®Google Scholar
• POLLOCK WK, ARMSTRONG RA, BRYDON LI JONES RL, MACINTYRE DE: Thromboxane-induced phosphati-date formation in human platelets. Relationship to receptor occupancy and to changes in cytosolic free calcium. Biochem. J. (1984) 219:833–842.
   Google Scholar
• KAWAHARA Y, YAMANISHI J, FURUTA Y, KAIBUCHI K, TAKAI Y, FUKUZAKI H: Elevation of cytoplasmic free calcium concentration by stable thromboxane Ay analogue in human platelets. Biochem. Biophys. Res. Commun. (1983) 17:663–669.
   Google Scholar
• LEDUC LE, WYCHE AA, SPRECHER H, SANKARAPPE SK, NEEDLEMAN P: Analogues of arachidonic acid used to evaluate structural determinants of prostaglandin receptor and enzyme specificities. Mol Pharmacol. (1981) 19:242–247.
   PubMedGoogle Scholar
• ARMSTRONG RA, JONES RL, PEESAPATI V, WILL SG, WILSON NH: Competitive antagonism at thromboxane receptors in human platelets. Br. J. Pharmacol. (1985) 84:595–607.
   PubMedGoogle Scholar
• BALDASSARE JJ, TARVER AP, HENDERSON PA, MACKINWM, SAHAGAN B, FISHER GJ: Reconstitution of thromboxane A2 receptor-stimulated phosphoinosi-tide hydrolysis in isolated platelet membranes: involvement of phosphoinositide-specific phospholi-pase c-p and GTP-binding Gq. Biochem. J. (1993) 291:235–240.
   PubMed Web of Science ®Google Scholar
• SMITH JB, ARAKI H, LEFER AM: Thromboxane A2, prostacyclin and aspirin: effects on vascular tone and platelet aggregation. Circulation (1980) 62:V19–V25.
   Google Scholar
• GOLINO P, ASHTON JH, BUJA LM et al.: Local plateletactivation causes vasoconstriction of large epicardial canine coronary arteries in vivo: thromboxane A2 and serotonin are possible mediators. Circulation (1989) 79:154–166.
   PubMed Web of Science ®Google Scholar
• HIRATA Y, UMEMURA K, NAKANO M, UEMATSU T, NAKASHIMA M: Enhancement of thrombotic arterial occlusion following cholesterol feeding in the guinea pig: a role for thromboxane A2. Prostaglandines Leukotrienes Essent. Fat Oi Acids (1994) 51:81–86.
   Google Scholar
• KOBILKA BK, MATSUI H, KOBILKA TS et al.: Cloning,sequencing, and expression of the gene coding for the human platelet a2-adrenergic receptor. Science (1987) 238:650–656.
   PubMed Web of Science ®Google Scholar
• SPALDING A, VAITKEVICIUS H, DILL S, MACKENZIE S,SCHMAIER A, LOCKETTE W: Mechanism of epinephrine-induced platelet aggregation. Hyperten-sion (1998) 31:603–607.
   PubMed Web of Science ®Google Scholar
• •Role of adrenaline in the aggregation process.
   Google Scholar
• LEYSEN J, GOMMEREN W, DE CLERCK F: Demonstrationof S2-receptor binding sites on cat blood platelets using [311]ketanserin. Eur. J. Pharmacol. (1983) 88:125–129.
   PubMedGoogle Scholar
• COHEN ML, MASON N, WILEY KS, FULLER RW: Furtherevidence that vascular serotonin receptors are of the 5-11T2 type. Biochem. Pharmacol (1983) 32:567–570.
   PubMedGoogle Scholar
• COOK EH, FLETCHER KE, WAINWRIGHT M, MARKS N, YAN SY, LEVENTHAL BL: Primary structure of the human platelet serotonin 5-HT2A receptor: identify with frontal cortex serotonin 5-HT2A receptor. J. Neurochem. (1994) 63:465–469.
   PubMedGoogle Scholar
• HOURANI SMO, CUSACK NJ: Pharmacological receptors on blood platelets. Pharmacol. Rev. (1991) 43:243–298.
   PubMed Web of Science ®Google Scholar
• ••Overview of platelet receptors.
   Google Scholar
• LI N, WALLEN NH, LADJEVARDI M, HJEMDAHL P: Effects of serotonin on platelet activation in whole blood. Blood Coagul. Fibrinol. (1997) 8:517–523.
   PubMed Web of Science ®Google Scholar
• •Role of serotonin in platelet activation.
   Google Scholar
• OGAWA T, SUGIDACHI A, ASAI F, KOIKE H: Involvement of platelet-derived 5-hydroxytryptamine in thromboxane A2-induced aggregation in cat platelets. Blood Coagul. Fibrinol. (1998) 9:233–240.
   PubMedGoogle Scholar
• CHIGNARD M, LE COUEDIC JP, VARGAFTIG BB, BENVEN-ISTE J: The role of platelet activating factor in platelet aggregation. Nature (1979) 279:799–800.
   PubMed Web of Science ®Google Scholar
• •Review of platelet activating factor mediated platelet stimulation.
   Google Scholar
• NAKAMURA M, HONDA Z, IZUMI T et al.: Molecularcloning and expression of platelet-activating factor receptor from human leukocytes. J. Biol. Chem. (1991) 266:20400–20405.
   PubMed Web of Science ®Google Scholar
• THIBONNIER M: The human platelet vasopressin receptor identification by direct ultraviolet photoaf-finity labeling. J. Biol. Chem. (1987) 262:10960–10964.
   PubMedGoogle Scholar
• LAUNAY JM, VITTET D, VIDAUD M et al.:Via-vasopressin specific receptors on human platelets: potentiation by ADP and epinephrine and evidence for homologous down-regulation. Thromb. Res. (1987) 45:323–331.
   PubMedGoogle Scholar
• WUN T, PAGLIERONI T, LACHANT NA: Physiologic concentrations of arginine vasopressin activate human platelets in vitro. Br. J. Haematol. (1996) 92:968–972.
   PubMed Web of Science ®Google Scholar
• POLLOCK WK, MACINTYRE DE: Desensitization and antagonism of vasopressin-induced phosphoinositide metabolism and elevation of cytosolic free calcium concentration in human platelets. Biochem. J. (1986) 234:67–73.
   PubMedGoogle Scholar
• ALEXANDER JH, HARRINGTON RA: Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT. Drugs (1998) 56:965–976.
   Google Scholar
• •Comprehensive review of clinical trials on antiplatelet drugs.
   Google Scholar
• COLLER BS: Blockade of platelet GP Ilb/IIIa receptors as an antithrombotic strategy. Circulation (1995) 92:2373–2380.
   PubMed Web of Science ®Google Scholar
• •GP IIb/IIIa inhibitors as antiplatelet drugs.
   Google Scholar
• COLLER BS, PEERSCHKE El, SCUDDER LE, SULLIVAN CA: A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoprotein lib and/or Ma. J. Clin. Invest. (1983) 72:325:338.
   Google Scholar
• THE EPIC INVESTIGATORS: Use of a monoclonal antibody directed against the platelet glycoprotein Ilb/IIIa receptor in high-risk coronary angioplasty. New Engl. J. Med. (1994) 330:956–961.
   PubMed Web of Science ®Google Scholar
• THE EPILOG INVESTIGATORS: Platelet glycoprotein Ilb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization. New Engl. J. Med. (1997) 336:1689–1696.
   PubMed Web of Science ®Google Scholar
• THE EPISTENT INVESTIGATORS: Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-Ilb/Illa blockade. Lancet (1998) 352:87–92.
   PubMed Web of Science ®Google Scholar
• REOPRO AND PRIMARY PTCA ORGANIZATION AND RANDOMIZED TRIAL (RAPPORT) INVESTIGATORS: Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circula-tion (1998) 98:734–741.
   PubMedGoogle Scholar
• FELDING-HABERMANN B, CHERESH DA: Vitronectin and its receptors. Curr. Opin. Cell Biol. (1993) 5:864–868.
   PubMed Web of Science ®Google Scholar
• •Review of the role of vitronectin.
   Google Scholar
• SCARBOROUGH RM, ROSE JW, HSU HM et al.: Barbourin:a GP Ilb/IIIa specific integrin antagonist from the venom Sisturus M barbouri. J. Biol. Chem. (1991) 266:9359–9362.
   PubMed Web of Science ®Google Scholar
• SCARBOROUGH RM, NAUGHTON MA, TENG W et al.:Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycopro-tein Ilb/IIIa. J. Biol. Chem. (1993) 268:1066–1073.
   Google Scholar
• •Drug design of GP IIb/IIIa antagonists.
   Google Scholar
• NICHOLS AJ, RUFFOLO RR, HUFFMANN WF et al.: Development of GP Ilb/IIIa antagonists as antithrom-botic drugs. Trends Pharmacol. Sci. (1992) 13:413–417.
   PubMed Web of Science ®Google Scholar
• •The future of anti-integrins as antiplatelet drugs.
   Google Scholar
• GOA KL, NOBLE S: Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Drugs (1999) 57:439–462.
   PubMed Web of Science ®Google Scholar
• THE PURSUIT TRIAL INVESTIGATORS: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. New Engl. J. Med. (1998) 339:436–443.
   PubMed Web of Science ®Google Scholar
• THE IMPACT II INVESTIGATORS: Randomised placebo-controlled trial of effect of eptifibatide on complica-tions of percutaneous coronary intervention: IMPACT II. Lancet (1997) 349:1422–1428.
   PubMed Web of Science ®Google Scholar
• THE IMPACT-AMI INVESTIGATORS: Combined acceler-ated tissue-plasminogen activator and platelet glycoprotein Ilb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. Circulation (1997) 95:846–854.
   PubMedGoogle Scholar
• DOOLEY M, GOA KL: Lamifiban. Drugs (1999) 57:215–221.
   PubMed Web of Science ®Google Scholar
• •Overview of the properties of lamifiban.
   Google Scholar
• THE PARAGON INVESTIGATORS: International randomized controlled trial of Lamifiban (a platelet glycoprotein Ilb/IIIa inhibitor), heparin, or both in unstable angina. Circulation (1998) 97:2386–2395.
   PubMed Web of Science ®Google Scholar
• MOLITERNO DJ, HARRINGTON RA, NEWBY KL et al.: Late diverging event curves for survival following Ilb/IIIa antagonismin patients with unstable angina:PARAGON Study 1-year follow up. J. Am. Coll Cardiol. (1998) 31 (Supp. A):A–208.
   Google Scholar
• WELLER T, AUG L, BERESINI M et al.: Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines. J. Med. Chem. (1996) 39:3139–3147.
   Google Scholar
• DOOLEY M, GOA KL: Sibrafiban. Drugs (1999) 57:225–230.
   PubMedGoogle Scholar
• •Overview of the properties of sibrafiban.
   Google Scholar
• WITTKE B, MACKIE IJ, MACHIN SJ, TIMM U, ZELL M, GOGGIN T: Pharmacokinetics and pharmacody-namics of Ro-443888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers. Br. J. Clin. Pharmacol. (1999) 47:521–530.
   PubMed Web of Science ®Google Scholar
• CANNON CP, MCCABE CH, BORZAK S et al: Randomizedtrial of an oral platelet glycoprotein Ilb/IIIa antago-nist, sibrafiban, in patients after an acute coronary syndrome; results of the TIMI 12 trial. Thrombolysis in Myocardial Infarction. Circulation (1998) 97:340–349.
   PubMed Web of Science ®Google Scholar
• THE PLATELET RECEPTOR INHIBITION IN ISCHEMIC SYNDROME MANAGEMENT (PRISM) STUDY INVESTIGA-TORS: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. New Engl. J. Med. (1998) 338:1498–1505.
   PubMed Web of Science ®Google Scholar
• THE PLATELET RECEPTOR INHIBITION IN ISCHEMIC SYNDROME MANAGEMENT IN PATIENTS LIMITED BY UNSTABLE SIGNS AND SYMPTOMS (PRISM-PLUS) STUDY INVESTIGATORS: Inhibition of the platelet glycopro-tein Ilb/IIIa receptor with tirofiban in unsTable angina and non-Q-wave myocardial infarction. New Engl. J. Med. (1998) 338:1488–1497.
   PubMedGoogle Scholar
• THE RESTORE INVESTIGATORS: Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. J. Am. Coll. Cardiol (1998) 32:28–34.
   PubMedGoogle Scholar
• GAARDNER A, JONSEN J, LALAND S, HELLEM A, OWEN PA: Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature (1961) 192:531–532.
   PubMed Web of Science ®Google Scholar
• HECHLER B, VIGNE P, LEON C, BREITTMAYER J-P, GACHET C, FRELIN C: ATP derivatives are antagonists of the P2Y1 receptor: similarities to the platelet ADP receptor. Mol. Pharmacol (1998) 53:727–733.
   PubMed Web of Science ®Google Scholar
• HUMPHRIES RG, TOMLINSON W, INGALL AH, CAGE PA, LEFF P: FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T-purinoceptors. Br. J. Pharmacol. (1994) 113:1057–1063.
   PubMed Web of Science ®Google Scholar
• HUMPHRIES RG, TOMLINSON W, CLEGG JA, INGALL AH, KINDON ND, LEFF P: Pharmacological profile of the novel P2T purinoceptor antagonist FPL 67085 in vitro and in the anaesthetised rat in vivo. Br. J. Pharmacol. (1995) 115:1110–1116.
   PubMedGoogle Scholar
• THEBAULT JJ, BLATRIX CE, BLANCHARD JF, PANAK EA: Effects of ticlopidine, a new platelet aggregation inhibitor in man. Clin. Pharmacol Ther. (1975) 18:485–490.
   PubMed Web of Science ®Google Scholar
• MCTAVISH D, FAULDS D, GOA KL: Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs (1990) 40:238–259.
   Google Scholar
• GENT M, BLAKELY JA, EASTON JD et al.: The CanadianAmerican Ticlopidin Study (CATS) in thromboembolic stroke. Lancet (1989) 333:1215–1220.
   Google Scholar
• HASS WK, EASTON JD, ADAMS HR et al.: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. New Engl. J. Med. (1989) 321:501–507.
   PubMed Web of Science ®Google Scholar
• SCHROR K: The basic pharmacology of ticlopidine and clopidogrel. Platelets (1993) 4:252–261.
   PubMed Web of Science ®Google Scholar
• •Overview of the properties of ticlopidin and clopidogrel.
   Google Scholar
• COUKELL AJ, MARKHAM A: Clopidogrel. Drugs (1997) 54:745–750.
   PubMed Web of Science ®Google Scholar
• •Overview of the properties of clopidogrel.
   Google Scholar
• HERBERT JM: Clopidogrel and antiplatelet therapy. Exp. Opin. Invest. Drug (1994) 3(5):449–455.
   Google Scholar
• SAVI P, HERBERT JM, PFLIEGER AM et al.: Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem. Pharmacol. (1992) 44:527–532.
   PubMed Web of Science ®Google Scholar
• SAVI P, COMBALBERT J, GAICH C et al: The antiaggre-gating activity of clopidogrel is due to metabolic activa-tion by the hepatic cytochrome P450-1A. Thromb. HaemosL (1994) 72:313–317.
   PubMed Web of Science ®Google Scholar
• WEBER A-A, REIMANN S, SCHROR K: Specific inhibition of ADP induced platelet aggregation by clopidogrel in vitro. Br. J. Pharmacol. (1999) 126:415–420.
   PubMedGoogle Scholar
• SAVI P, HEILMANN E, NURDEN P et al.: Clopidogrel: an antithrombotic drug acting on the ADP-dependent activation pathway of human platelets. Clin. Appl. Thromb. HaemosL (1996) 2:35–42.
   Web of Science ®Google Scholar
• ASZODI A, PFEIFER A, AHMAD M et al.: The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO J (1999) 18:37–48.
   PubMed Web of Science ®Google Scholar
• HAUSER W, KNOBELOCH K-P, EIGENTHALER M et al.: Megakaryocyte hyperblasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice. Proc. Natl. Acad. Sci. USA (1999) 96:8120–8125.
   PubMedGoogle Scholar
• REINHARD M, JARCHAU T, REINHARD K, WALTER U: VASP. In: Guidebook to the Cytoskeletal and Motor Proteins. Kreis T, Vale R (Eds.), Oxford University Press, New York, USA (1999):168–171.
   Google Scholar
• CAPRIE STEERING COMITTEE: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet (1996) 348:1329–1339.
   PubMedGoogle Scholar
• CARPORT STUDY GROUP: Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2 receptor blockade. Circulation (1991) 84:1568–1580.
   PubMedGoogle Scholar
• THE RAPT INVESTIGATORS: Randomized trial of Ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocar-dial infarction. Circulation (1994) 89:588–595.
   PubMedGoogle Scholar
• GRESELE P, DECKMYN H, NENCI GG, VERMYLEN J: Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. Trends Pharmacol. Sci. (1991) 12:158–163.
   PubMed Web of Science ®Google Scholar
• ••Overview of thromboxane antagonists.
   Google Scholar
• PATSCHEKE H, STEGMEIER K: Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets. Thromb. Res. (1984) 33:277–288.
   Google Scholar
• STEGMEIER K, PILL J, MULLER-BECKMANN B et al.: The pharmacological profile of the thromboxane A2 antagonist BM 13.177. A new anti-platelet and anti-thrombotic drug. Thromb. Res. (1984) 35:379–395.
   Google Scholar
• SOYKA R, HECKEL A, NICKL J, EISERT W, MOLLER TH, WEISENBERGER H: 6,6 Disubstituted hex-5-enoic acid derivatives as combined thromboxane Ay receptor antagonists and synthetase inhibitors. J. Med. Chem. (1994) 37:26–39.
   PubMed Web of Science ®Google Scholar
• ESATO K, KUBO Y, YASUDA K et al.: Satigrel, a new antiplatelet agent, inhibits platelet accumulation in prosthetic arterial grafts. Am. J. Surg. (1998) 175:56–60.
   PubMedGoogle Scholar
• NAGAKURA N, SAEKI T, HARADA K et al. Mechanism of satigrel (E 5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthase isozym activities and phosphodiesterase isoform activities. Biol. Pharm. Bull. (1996) 19:828–833.
   Google Scholar
• GRESELE P, DECKMYN H, ARNOUT J, NENCI GG, VERMYLEN J: Characterization of N,N'-bis(3-picoly0-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets. Thromb. HaemosL (1989) 61:479–484.
   PubMed Web of Science ®Google Scholar
• YUE TL, SMITH EF, OHLSTEIN EH et al.: Pharmacological profile of G619, a new platelet aggregation inhibitor. Thromb. Res. (1992) 66:331–347.
   PubMed Web of Science ®Google Scholar
• COCOZZA M, MILANI M, PICANO T, OLIVIERO U, RUSSO N, COTO V: Antiaggregatory effects of picotamide in long-term treatment: a 2-year, double-blind placebo-controlled trial. Vasc. Med. (1997) 2:292–295.
   PubMedGoogle Scholar
• STONE SR, HOFSTEENGE J: Kinetics of inhibition of thrombin by hirudin. Biochem. (1986) 25:4622–4628.
   PubMed Web of Science ®Google Scholar
• ORGANIZATION TO ASSESS STRATEGIES FOR ISCHEMIC SYNDROMES (OASIS) INVESTIGATORS: Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocar-dial ischemia without ST elevation: a pilot study. Circulation (1997) 96:769–777.
   PubMed Web of Science ®Google Scholar
• ORGANIZATION TO ASSESS STRATEGIES FOR ISCHEMIC SYNDROMES (OASIS-2) INVESTIGATORS: Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet (1999) 353:429–438.
   PubMed Web of Science ®Google Scholar
• THE HIRULOG ANGIOPLASTY STUDY INVESTIGATORS: Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. New Engl. J. Med. (1995) 333:764–769.
   PubMedGoogle Scholar
• BITTL JA: Clinical trials of Hirulog in patients undergoing high-risk percutaneous transluminal coronary angioplasty. Coron. Artery Dis. (1996) 7:449–454.
   PubMed Web of Science ®Google Scholar
• THE HERO TRIAL INVESTIGATORS: Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation (1997) 96:2155–2161.
   PubMedGoogle Scholar
• WHITE HD, ELLIS CJ, FRENCH JK, AYLWARD P: Hirudin (de sirudin) and hirulog (bivalirudin) in acute ischaemic syndromes and the rationale for the hirulog/early reperfusion occlusion (HERO-2) study. Aust. NZ. J Med. (1998) 28:551–554.
   PubMedGoogle Scholar
• JAKUBOWSKI JA, MARAGANORE JM: Inhibition of coagulation and thrombin-induced platelet activation by a synthetic dodecapeptide modeled on the carboxy terminus of hirudin. Blood (1990) 75:399–406.
   PubMedGoogle Scholar
• CO MS, YANO S, HSU RK et al.: A humanized antibody specific for the platelet integrin gpfib/IIIa. j Immunol. (1994) 152:2968–2976.
   PubMedGoogle Scholar
• YANO S, SUZUKI K, KATOH M et al.: Epitopes and biological activities of two monoclonal antibodies to platelet integrin all6133. j Biochem. (Tokyo) (1994) 116:778–7786.
   PubMedGoogle Scholar
• KUWAHARA M, SUGIMOTO M, TSUJI S et al.: Compara-tive studies on the antiplatelet effects of a humanized antiplatelet glycoprotein Ilb/Ifia antibody (YM 337) and ReoPro under flow conditions. Thromb. HaemosL (1998) 80:28–31.
   PubMed Web of Science ®Google Scholar
• KAWASAKI T, SATO K, SUZUKI K et al: Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by combination with a humanized anti-glycoprotein Ilb/Ifia monoclonal antibody, YM 337, in a rhesus monkey model of coronary thrombosis. Thromb. HaemosL (1998) 79:663–667.
   PubMedGoogle Scholar
• KAKU S, UMEMURA K, MIZUNO A et al.: Evaluation of a GP Ilb/Ifia antagonist YM 337 in a primate model of middle cerebral artery thrombosis. Eur. J. Pharmacol (1998) 345:185–192.
   PubMed Web of Science ®Google Scholar
• WITTIG K, ROTHE G, SCHMITZ G: Inhibition of fibrinogen binding and surface recruitment of GP Ilb/Ifia as dose-dependent effects of the RGD-mimetic MK-852. Thromb. HaemosL (1998) 79:625–630.
   PubMedGoogle Scholar
• MICHAELIS W, TURLAPATY P, GRAY J eta].: Pharmacody-namics and pharmacokinetics of DMP 728, a platelet GP Hb/IIIa antagonist, in healthy subjects. Clin. Pharmacol. Thar. (1998) 63:384–392.
   Google Scholar
• KEREIAKES DJ, KLEIMAN N, FERGUSON JJ et al.: Sustained platelet glycoprotein Ilb/Ifia blockade with oral xemilofiban in 170 patients after coronary stent deployment. Circulation (1997) 96:1117–1121.
   PubMed Web of Science ®Google Scholar
• KEREIAKES DJ, KLEIMAN N, FERGUSON JJ et al.: Pharma-codynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein fib/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial. Circulation (1998) 98:1268–1278.
   PubMed Web of Science ®Google Scholar
• OKOMURA K, SHIMAZAKI T, AOKI Y et al.: New platelet fibrinogen receptor glycoprotein Ilb-Ifia antagonists: orally active series of N-alkylated amidines with a 6,6-bicyclic template. J. Med. Chem. (1998) 41:4036–4052.
   PubMedGoogle Scholar
• BANNO H, KAWAZURA H, YUTAKA T et al.: Antiaggrega-tory, antithrombotic effects of MS-180, a novel platelet glycoprotein Hb/IIIa receptor antagonist. Eur. J. Pharmacol. (1999) 367:275–282.
   PubMedGoogle Scholar
• REBELLO SS, HUANG J, SHIU WJ eta].: Pharmacokinetics and pharmacodynamics of SM-20302, a GPIlb/IIIa receptor antagonist, in anesthetized dogs. J. Cardio-vasc. Pharmacol. (1998) 32:485–494.
   Google Scholar
• REBELLO SS, HUANG J, SAITO K, LUCCHESI BR: In vivo efficacy of SM-20302, a GP Ilb/Ifia receptor antagonist, correlates with ex vivo platelet inhibition in heparinized blood but not in citrated blood. Arterio-scler. Thromb. Vasc. Biol. (1998) 18:954–960.
   PubMedGoogle Scholar
• HUANG J, REBELLO SS, ROSENBERG LA, KANEKO M, SAKURAMA T, LUCCHESI BR: Temporary and partial inhibition of platelets by SM-20302 prevents coronary artery thrombosis in a chronic canine model. Eur. J. Pharmacol. (1999) 366:203–213.
   PubMedGoogle Scholar
• HOFFMANN P, BERNAT A, SAVI P, HERBERT JM: Antiplatelet and antithrombotic efficacy of SR 121787, a nonpeptide orally active GP Ilb/Ifia antagonist, in rabbits: comparison with clopidogrel and aspirin. J. Cardiovasc. Pharmacol (1997) 30:360–366.
   PubMedGoogle Scholar
• MOLLER TH, WEISENBERGER H, BRICKL R, NARJES H, MIMMELSBACH F, KRAUSE J: Profound and sustained inhibition of platelet aggregation by fradafiban, a nonpeptide platelet glycoprotein Ilb/Ifia antagonist, and its orally active prodrug, lefradafiban, in men. Circulation (1997) 96:1130–1138.
   PubMedGoogle Scholar
• BELLINGER DA, NICHOLS TC, READ MS et al.: Prevention of occlusive coronary artery thrombosis by a murine monoclonal antibody to porcine von Willebrand factor. Proc. Natl. Acad. ScL USA (1987) 84:8100–8104.
   PubMedGoogle Scholar
• MILLER JL, THIAM-CISSE M, DROUET LO: Reduction in thrombus-formation by PG-1 (Fab'), and anti-guinea pig platelet glycoprotein lb monoclonal antibody. Arterioscler. Thromb. (1991) 11:1231–1236.
   PubMedGoogle Scholar
• KRUPSKI WC, BASS A, CADROY Y et al.: Antihemostatic and antithrombotic effects of monoclonal antibodies against von Willebrand factor in nonhuman primates. Surgery (1992) 112:433–439.
   PubMedGoogle Scholar
• KAGEYAMA S, YAMAMOTO H, NAGANO M, ARISAKA H, KAYAHARA T, YOSHIMOTO R: Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor. Br. J. Pharmacol (1997) 122:165–171.
   PubMed Web of Science ®Google Scholar
• ANDRE P, HAMAUD P, BAL-DIT-SOLLIER C et al.: Guinea pig blood: a model for the pharmacologic modulation of the GPIb/IX-vWF axis. Thromb. Res. (1996) 83:127–36.
   PubMedGoogle Scholar
• INGALL AH, DIXON J, BAILEY A et al.: Anatgonists of the platelet P2T receptor: a novel approach to antithrom-botic therapy. J. Med. Chem. (1999) 42:213–220.
   PubMed Web of Science ®Google Scholar
• •New development of platelet purinoceptor antagonists.
   Google Scholar
• LAUBINGER W, REISER G: Evidence for a G protein-coupled di ade no si ne -5 ',5"'-P1, P4 -tetrap hos p hate (Ap4A) receptor binding site in lung membranes from rat. Eur. J. Pharmacol. (1999) 366:93–100.
   PubMedGoogle Scholar
• KISSELEV LL, JUSTESEN J, WOLFSON AD, FROLOVA LY: Diadenosine oligophosphates (Ap(n)A), a novel class of signalling molecules? FEBS Lett. (1998) 427:157–163.
   Google Scholar
• OGILVIE A, BLASIUS R, SCHULZE-LOHOFF E, STERZEL RB: Adenine dinucleotides: a novel class of signalling molecules. J. Auton. Pharmacol. (1996) 16:325–328.
   PubMedGoogle Scholar
• CHAN SW, GALLO SJ, KIM BK, GUO MJ, BLACKBURN GM, ZAMECNIK PC: P1,P4-Dithio-P2,P3-mono- chlorometh-ylene diadenosine 5',5"-P1,P4-tetra phosphate: a novel antiplatelet agent. Proc. Natl. Acad. ScL USA (1997) 94:4034–4039.
   PubMedGoogle Scholar
• SOYKA R, GUTH BD, WEISENBERGER HM, LUGER P, MOLLER TH: Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors. J. Med. Chem. (1999) 42:1235–1249.
   PubMed Web of Science ®Google Scholar
• MUCK S, WEBER A-A, SCHROR K: Effects of terbogrel on platelet function and prostaglandin endoperoxide transfer. Eur. J. Pharmacol. (1998) 344:45–48.
   PubMedGoogle Scholar
• TANAKA T, FUKUTA Y, HIGASHINO R et al.: Antiplatelet effect of Z-335, a new orally active and long lasting thromboxane receptor antagonist. Eur. J. Pharmacol (1998) 357:53–60.
   PubMedGoogle Scholar
• FINKLE CD, ST. PIERRE A, LEBLOND L, DESCHENES I, DIMAIO J, WINOCOUR PD: BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis - comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Thromb. HaemosL (1998) 79:431–438.
   PubMedGoogle Scholar
• BUSH LR: Argatroban, a selective, potent thrombin inhibitor. Cardiovasc. Drug Rev. (1991) 9:247–263.
   Google Scholar
• HURSTING MJ, ALFORD KL, BECKER JC et al.: Novastan (brand of argatroban): a small molecule, direct thrombin inhibitor. Semin. Thromb. Hemost. (1997) 23:503–516.
   PubMed Web of Science ®Google Scholar
• •Overview of the properties of argatroban.
   Google Scholar
• KOBAYASHI S, TAZAKI Y: Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Semin. Thromb. HemosL (1997) 23:531–534.
   PubMed Web of Science ®Google Scholar
• SUZUKI S, SAKAMOTO S, KOIDE M, MATSUO M, FUJII K, MATSUO T: Effective anticoagulation by argatroban during coronary stent implantation in a patient with heparin-induced thrombocytopenia. Thromb. Res. (1997) 88:499–502.
   PubMedGoogle Scholar
• LEWIS BE, RANGEL Y, FAREED J: The first report of successful carotid stent implant using argatroban anticoagulation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome: a case report. Angiology (1998) 49:61–67.
   PubMed Web of Science ®Google Scholar
• NILSSON T, SJOLING-ERICKSSON A, DEINUM J: The mechanism of binding of low-molecular-weight active site inhibitors to human a-thrombin. J. Enzyme Inhibit. (1988) 13:11–29.
   Google Scholar
• HIRSH J, WEITZ JI: Thrombosis: new antithrombotic agents. Lancet (1999) 353:1431–1436.
   PubMed Web of Science ®Google Scholar
• •Review of recent development in anti-aggregatory treatment.
   Google Scholar
• THE TRIM STUDY GROUP: A low molecular weight, selective thrombin inhibitor, inogatran, vs. heparin, in unstable coronary artery disease in 1209 patients: a double-blind, randomized, dose-finding study. Eur. Heart J. (1997) 18:1416–1425.
   Google Scholar
• GRIP L, FRISON L, WALLENTIN L: A low molecular weight, selective thrombin inhibitor, inogatran, vs. heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Eur. Heart J. (1997) 18:1416–1425.
   Google Scholar
• GUSTAFSSON D, ANTONSSON T, BYLUND R et al.: Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb. HaemosL (1998) 79:110–118.
   PubMed Web of Science ®Google Scholar
• MARUYAMA K, KINAMI J, SUGITA Y et al.: MCI-9042: high affinity for serotonergic receptors as assessed by radioligand binding assay. J. Pharmacobiodyn. (1991) 14:177–181.
   PubMedGoogle Scholar
• NISHIO H, INOUE A, NAKATA Y: Binding affinity of sarpogrelate, a new antiplatelet agent, and its metabo-lite for serotonin receptor subtypes. Arch. Int. Pharma-codyn. (1996) 331:189–202.
   PubMedGoogle Scholar
• HARA H, OSAKABE M, KITAJIMA A, TAMAO Y, KIKUMOTO R: MCI-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist. Thromb. HaemosL (1991) 65:415–420.
   PubMed Web of Science ®Google Scholar
• AIHARA M, ISHII K, HARA K, KOSAKAI H, NINOMIYA K: Prevention of post PTCA restenosis with the serotonin antagonist sarpogrelate hydrochloride. Jap. J. Interven. Cardiol (1997) 12:83–87.
   Google Scholar